Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis. It has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.

• Download SqueezeTrigger (TM) Report
• Download FrictionFactor Report
• Download Daily Short Volume Report
• Download Real-Time Short Volume Tool
• Download Failures to Deliver

• [09/08/2026 13:58 PDT] Nkarta, Inc. (NASDAQ:NKTX), Up By 100% ($2.47) From $2.47 After BUYINS.NET Report Predicted Stock Would Go Up Due To Bullish Conditions
• [08/21/2026 07:28 PDT] NKTX Expected to Trade Up After Bullish Patterns Develop
• [07/30/2026 06:51 PDT] NKTX Expected to Trade Down After Bearish Patterns Develop
• [07/28/2026 11:07 PDT] Nkarta, Inc. (NASDAQ:NKTX), Down By 100% ($2.65) From $2.65 After BUYINS.NET Report Predicted Stock Would Go Down Due To Bearish Conditions
• [07/21/2026 06:43 PDT] NKTX Expected to Trade Up After Bullish Patterns Develop
• [07/15/2026 06:42 PDT] NKTX Expected to Trade Down After Bearish Patterns Develop